To the Editor As part of a study using clinical data linked to comprehensive genomic profiling results obtained from routine care, Dr Singal and colleagues1 explored programmed death-ligand 1 (PD-L1) status and clinical outcomes among patients with non–small cell lung cancer (NSCLC) who received anti–programmed cell death protein 1 (PD-1)/PD-L1 therapy. They found that PD-L1 status (negative vs positive; 50% staining as cutoff) was not related to overall survival, regardless of treatment line. However, patients receiving different treatment lines should be analyzed separately. The KEYNOTE-042 study2 and KEYNOTE-024 study3 indicated that the overall survival of patients with NSCLC administered pembrolizumab as first-line therapy was dependent on PD-L1 status.
Yang X, Qi C, Ji M. PD-L1 Status and Survival in Patients With Lung Cancer. JAMA. 2019;322(8):783. doi:https://doi.org/10.1001/jama.2019.9177
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: